KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Non-Current Debt (2024 - 2025)

Historic Non-Current Debt for Esperion Therapeutics (ESPR) over the last 2 years, with Q3 2025 value amounting to $151.7 million.

  • Esperion Therapeutics' Non-Current Debt changed N/A to $151.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $151.7 million, marking a year-over-year change of. This contributed to the annual value of $141.0 million for FY2024, which is N/A changed from last year.
  • As of Q3 2025, Esperion Therapeutics' Non-Current Debt stood at $151.7 million.
  • Over the past 5 years, Esperion Therapeutics' Non-Current Debt peaked at $151.7 million during Q3 2025, and registered a low of $141.0 million during Q4 2024.